

Date: 22 January 2025

To

The Secretary BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400 001 Scrip Code: 544293	The Secretary The National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1. G Block Bandra -Kurla Complex, Bandra (East) Mumbai- 400 051 Scrip Symbol : SURAKSHA
---	--

Dear Sir / Ma'am,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015- Incorporation of subsidiary of the Company

This is in furtherance of our intimation dated 20 December 2024, wherein we had informed that the Board of Directors of the Company in its meeting held on 20 December 2024, had approved incorporation of a Special Purpose Vehicle Company, as a subsidiary of the Company in India, and the details in terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Schedule III Part A, Para A, point 1 of SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/ CIR/P/0155 dated 11 November 2024 were given in the said intimation. A copy of the said intimation is annexed for your kind reference.

In this connection, we would like to inform you that “**Suraksha Advanced Radiology Private Limited**” (CIN- U86905WB2025PTC275806) had been incorporated on 18 January 2025 as a subsidiary of the Company, having its registered office at Plot No. DG-12/1, Action Area 1D, Premises No 02-0327, New Town, North 24 Parganas, Kolkata- 700 156, West Bengal, India.

You are requested to kindly take the same on record.

Thanking you.

For **Suraksha Diagnostic Limited**

Mamta Jain

Company Secretary and Compliance Officer
Membership No.: ACS 25654

Encl : as above

Date: 20 December 2024

To,
The Head, Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
Scrip Code: 544293

To,
The Head, Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1. G Block
Bandra - Kurla Complex, Bandra (East)
Mumbai- 400 051
Scrip Symbol : SURAKSHA

Dear Sir / Ma'am,

Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sub: Outcome of Board Meeting held on 20 December 2024

With reference to our earlier intimation dated 14 December 2024, the Board of Directors of the Company at its meeting held on 20 December 2024 have, inter alia, considered and approved the following matters:

1. Unaudited Financial Results (Standalone and Consolidated) of the Company for quarter and half year ended 30 September 2024 and the same is enclosed along with Limited Review Report issued by the Statutory Auditors of the Company and placed before the Board, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as "**Annexure-A**";
2. Postal Ballot Notice for seeking shareholders' approval for the ratification of 'Suraksha Employee Stock Option Scheme 2024' ("ESOP 2024" / "Scheme"). The notice of the Postal Ballot will be circulated to the shareholders and stock exchanges in due course;
3. Formation of a Special Purpose Vehicle Company ("SPV") between Suraksha Diagnostic Limited and Suraksha Diagnostic & Eye Centre Private Limited, along with the subscription to the equity shares of the SPV, to be incorporated. The SPV will focus on the establishment, operation, maintenance and management of 1.5 Tesla MRI Centre at Kolkata Medical College and Hospital, Kolkata on Public Private Partnerships (PPP) mode.

Details, as required under SEBI Circular No. SEBI/HO/CFD/PoD2/ CIR/P/0155 dated 11 November 2024, are enclosed as "**Annexure-B**".

Suraksha Diagnostic Limited

(Formerly known as Suraksha Diagnostic Private Limited)

CIN: U85110WB2005PLC102265

Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town,
Kolkata-700 156, West Bengal, India

E-mail: investors@surakshanet.com | **Website:** www.surakshanet.com

Phone:(033) 6605 9750


Please note that the meeting commenced at 11.45 am and concluded at 06.20 pm.

You are requested to take the same on record.

Thanking you.

For Suraksha Diagnostic Limited

**MAMTA
JAIN**



Digitally signed by MAMTA JAIN
DN: C=IN, O=Personal, T=0287, Phone=+919834931602, cn=MAMTA JAIN
c=IN, o=Personal, ou=0287, phone=+919834931602, cn=MAMTA JAIN
SERIALNUMBER=78bc99349330, CN=MAMTA JAIN
Reason: I am the author of this document
Date: 2024.12.20 18:21:22+05'30'
Font: PDF Editor Version: 2024.1.0

Mamta Jain
Company Secretary and Compliance Officer
Membership No.: ACS 25654

Encl.: As above

Annexure-B

Details required to be furnished in compliance with Regulation 30 read with Schedule III Part A, Para A, point 1 of SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/ CIR/P/0155 dated 11 November 2024:

a.	Name of the target entity, details in brief such as size, turnover etc.;	Suraksha Advanced Radiology Private Limited (proposed name) or any other name as may be approved by the Registrar of Companies. Size, turnover etc.: Not applicable.
b.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	The proposed Company would be a Subsidiary Company and post incorporation will be classified as a related party. Any transactions with the subsidiary, if undertaken, will be conducted on an arm's-length basis.
c.	Industry to which the entity being acquired belongs;	Business of running diagnostic centers
d.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The objective of the proposed Company is to establish, construct, erect, build, organize, manage, undertake, promote, improve, equip, initiate, encourage, provide, maintain, operate, conduct, subsidize, take on lease, own and run in India or abroad Diagnostic Centers, Scan Centers, Nursing Homes, Hospitals, Clinics, Polyclinics, Dispensaries, Chemist Shops, Blood Banks, Eye Banks, Kidney Banks, Maternity Homes, Child Welfare and Family Planning Centers, Clinical and Pathological Testing Laboratories, Consulting Chambers, X-Ray and ECG Clinics, Sonography Centers, CT-SCAN, MRI SCAN Physiotherapy Centers, Polio Clinics, Dialysis Centers, Research Laboratories & Centers, and to do all incidental acts and things necessary for attainment of the above objects.
e.	Brief details of any governmental or regulatory approvals required for the acquisition;	Not applicable

Suraksha Diagnostic Limited

(Formerly known as Suraksha Diagnostic Private Limited)

CIN: U85110WB2005PLC102265

Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata-700 156, West Bengal, India

E-mail: investors@surakshanet.com | **Website:** www.surakshanet.com

Phone:(033) 6605 9750

f.	Indicative time period for completion of the acquisition;	Not applicable
g.	Consideration - whether cash consideration or share swap or any other form and details of the same;	Subscription to the share capital by cash consideration
h.	Cost of acquisition and/or the price at which the shares are acquired;	The contribution to initial share capital will be made at face value
i.	Percentage of shareholding / control acquired and / or number of shares acquired;	74% (Seventy four percent)
j.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years' turnover, country in which the acquired entity has presence and any other significant information (in brief);	Not applicable

Suraksha Diagnostic Limited

(Formerly known as Suraksha Diagnostic Private Limited)

CIN: U85110WB2005PLC102265

Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata-700 156, West Bengal, India

E-mail: investors@surakshanet.com | **Website:** www.surakshanet.com

Phone:(033) 6605 9750